NFKB1 and acute respiratory distress syndrome: Further, multiple studies demonstrated that the NF-κB signaling pathway is a promising therapeutic target of ALI/ARDS and other inflammatory diseases, including arthritis, pulmonary fibrosis, asthma and hepatitis [17,18,21].